As of Nov 25
| +0.01 / +0.67%|
The 1 analysts offering 12-month price forecasts for Navidea Biopharmaceuticals Inc have a median target of 2.40, with a high estimate of 2.40 and a low estimate of 2.40. The median estimate represents a +58.94% increase from the last price of 1.51.
The current consensus among 1 polled investment analysts is to Buy stock in Navidea Biopharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.